THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 摘要 胰升糖素抑制剂普拉林肽和埃塞那肽在成年T2 DM患者中的应用已被证实，但关于儿童T2 DM的有效降糖效果的信息缺乏。我们实验室以前的研究表明，T2 DM儿童早期餐后高血糖并未减轻，这是导致显著餐后高血糖的原因之一。需要胰岛素治疗的T2 DM患儿存在胰岛素、胰淀素和GLP-1缺乏症。胰淀素和GLP-1都是内源性的胰高血糖素抑制因子。胰淀素类似物普拉林肽和GLP-1受体激动剂埃塞那肽的降糖和降糖作用将在需要胰岛素的T2 DM儿童中进行测试。将使用成人推荐的最低剂量。随着T2 DM在儿科人群中发病率的增加，我们有责任研究新的治疗方法，以努力改善血糖控制，预防与糖尿病相关的长期微血管和大血管并发症。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT The use of glucagon suppressors pramlintide and exenatide is well established in adult patients with T2DM, but there is a lack of information regarding an effective glucose lowering effect in pediatric T2DM. Previous studies from our laboratory showed that there is unabated early postprandial hyperglucagonemia in children with T2DM contributing to the marked postprandial hyperglycemia. There is insulin, amylin and GLP-1 deficiency in children with T2DM requiring insulin therapy. Both amylin and GLP-1 are potent endogenous glucagon suppressors. The glucose and glucagon lowering effect of the amylin analog pramlintide and the GLP-1 receptor agonist exenatide will be tested in insulin requiring children with T2DM. The lowest adult recommended doses would be used. With an increasing incidence of T2DM in the pediatric population, it is incumbent upon us to research new therapies in an effort to improve glycemic control and prevent the long-term micro and macrovascular complications associated with diabetes.